Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference

Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ: AMPH) will present at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, 2026 at 2:15 PM PT. Jack Zhang, CEO and President, and Bill Peters, CFO, will deliver the presentation. A live webcast will be available at http://ir.amphastar.com and will remain accessible for 30 days after the presentation.

Amphastar focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and sells insulin active pharmaceutical ingredient products. Most finished products are used in hospital or urgent care settings and are distributed via group purchasing organizations and drug wholesalers.

News Market Reaction – AMPH

-1.05%

1 alert

-1.05% News Effect

On the day this news was published, AMPH declined 1.05%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference date: January 14, 2026 Presentation time: 2:15 pm PT Webcast availability: 30 days +5 more

8 metrics

Conference date January 14, 2026 J.P. Morgan 2026 Healthcare Conference presentation date

Presentation time 2:15 pm PT Scheduled time for J.P. Morgan conference presentation

Webcast availability 30 days Duration webcast will remain accessible after presentation

Form 10-K year 2024 Annual Report on Form 10-K for year ended December 31, 2024

Form 10-Q date March 31, 2025 Quarter end for referenced Form 10-Q filing

Form 10-Q date June 30, 2025 Quarter end for referenced Form 10-Q filing

Form 10-Q date September 30, 2025 Quarter end for referenced Form 10-Q filing

Report filing date March 3, 2025 Filing date of Form 10-K for year ended December 31, 2024

Market Reality Check

Price: $27.67 Vol: Volume 298,254 is below t...

normal vol

$27.67 Last Close

Volume Volume 298,254 is below the 20-day average of 369,997, indicating muted trading ahead of the announcement. normal

Technical Shares at $27.62 are trading above the 200-day moving average of $25.60, reflecting a generally positive longer-term trend into this conference update.

Peers on Argus

Peers showed mixed moves, with examples including BGM up 7.48% and TLRY down 2.5...

1 Up

Peers showed mixed moves, with examples including BGM up 7.48% and TLRY down 2.53%. Only EVO appeared on the momentum scanner, up about 4.78% without related news, suggesting today’s AMPH move is more stock-specific than broad sector-driven.

Historical Context

5 past events · Latest: Dec 15 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 15	FDA approval	Positive	+4.1%	FDA approval of teriparatide injection ANDA, with planned U.S. commercial launch.
Nov 24	Conference appearance	Neutral	+2.7%	Participation in Piper Sandler healthcare conference fireside chat via webcast.
Nov 12	Conference appearance	Neutral	+2.5%	Jefferies Global Healthcare Conference fireside chat with webcast access.
Nov 06	Quarterly earnings	Positive	-4.3%	Q3 2025 earnings with strong revenues but impacted by litigation and R&D costs.
Oct 27	Earnings scheduling	Neutral	-2.0%	Announcement of Q3 2025 earnings release date and conference call details.

Pattern Detected

Recent news with clear fundamentals or regulatory catalysts, such as FDA approval, tended to see positive price alignment, while the latest earnings release showed a notable divergence with a negative reaction.

Recent Company History

This announcement continues Amphastar’s pattern of engaging with major healthcare investor conferences, following appearances at the Jefferies Global Healthcare Conference and the 37th Annual Piper Sandler Healthcare Conference in November–December 2025, both accompanied by modest share gains. In mid-December 2025, the company reported FDA approval of its teriparatide injection ANDA, with shares rising about 4.12%. Earlier, Q3 2025 earnings on November 6, 2025 saw revenues of $191.8M but a -4.27% price reaction, contrasting with generally positive responses to other recent updates.

Market Pulse Summary

This announcement outlines Amphastar’s upcoming presentation at the J.P. Morgan 2026 Healthcare Conf...

Analysis

This announcement outlines Amphastar’s upcoming presentation at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026, continuing a pattern of participation in major investor events. The webcast will remain available for 30 days, providing additional insight into management’s views on growth, product portfolio, and clinical development. In context of recent milestones such as FDA approval for teriparatide injection and Q3 2025 earnings, investors may focus on any updates to revenue drivers, pipeline progress, and regulatory timelines highlighted during the presentation.

Key Terms

active pharmaceutical ingredient, forward-looking statements, clinical settings, clinical trials, +4 more

8 terms

active pharmaceutical ingredient medical

"Additionally, the Company sells insulin active pharmaceutical ingredient products."

The active pharmaceutical ingredient (API) is the chemical or biological substance in a medicine that produces the intended therapeutic effect, separate from inactive ingredients like fillers, binders or coatings. Investors watch APIs closely because their source, patent status, manufacturing cost, quality controls and supply reliability drive a drug’s safety, regulatory approval, margin and commercial potential—like the engine in a car determining performance and value.

forward-looking statements regulatory

"Forward Looking Statements All statements in this press release..."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

clinical settings medical

"Most of the Company's finished products are used in hospital or urgent care clinical settings..."

Clinical settings are places where medical care or health research is given to patients—such as hospitals, doctors’ offices, outpatient clinics, or dedicated trial sites. For investors, evidence that a drug, device, or procedure works in clinical settings shows how it performs in real-world, regulated practice rather than just in laboratory conditions, which affects regulatory approval, doctor adoption, reimbursement, and the product’s commercial prospects; think of it like testing a product in a real store instead of a lab.

clinical trials medical

"the timing and results of clinical trials, the impact of our products..."

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

Form 10-K regulatory

"including in our Annual Report on Form 10-K for the year ended December 31, 2024..."

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

Form 10-Q regulatory

"in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025..."

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

Securities and Exchange Commission regulatory

"those described in Amphastar's filings with the Securities and Exchange Commission ("SEC")..."

A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.

group purchasing organizations technical

"and are primarily contracted and distributed through group purchasing organizations and drug wholesalers."

Group purchasing organizations are companies that negotiate bulk buying deals on behalf of a group of members—such as hospitals, clinics or other businesses—so members pay lower prices for supplies and services. For investors, GPOs matter because they influence cost structures and margins for their member buyers and suppliers: stronger GPO contracts can drive steady fee-based revenue for the GPO and shift pricing and sales volumes across connected suppliers, similar to a neighborhood buying club leveraging volume for discounts.

AI-generated analysis. Not financial advice.

RANCHO CUCAMONGA, CA / ACCESS Newswire / January 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14^th, 2026, at 2:15 pm PT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.

About Amphastar Pharmaceuticals, Inc.:

Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company's website at www.amphastar.com.

The Amphastar Pharmaceuticals' logo, and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to BAQSIMI^®, Primatene MIST^®, REXTOVY^®, Amphadase^®, and Cortrosyn^®, are the property of Amphastar Pharmaceuticals, Inc.

Forward Looking Statements

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our manufacturing in-house expertise, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 7, 2025, in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 6, 2025, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI^®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.

Contact:

Bill Peters
Chief Financial Officer
(909) 476-3416

SOURCE: Amphastar Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

FAQ

When will Amphastar (AMPH) present at the J.P. Morgan 2026 Healthcare Conference?

Amphastar will present on January 14, 2026 at 2:15 PM PT.

Who from Amphastar will present at the J.P. Morgan 2026 Healthcare Conference?

Jack Zhang, CEO and President, and Bill Peters, CFO will present for Amphastar.

Where can investors watch the Amphastar (AMPH) webcast for the J.P. Morgan presentation?

The live webcast is available at http://ir.amphastar.com.

How long will the Amphastar (AMPH) J.P. Morgan webcast remain available after the presentation?

The webcast will be available for 30 days following the presentation.

What products and markets does Amphastar (AMPH) focus on?

Amphastar focuses on injectable, inhalation, and intranasal generic and proprietary products and sells insulin active pharmaceutical ingredient products used mainly in hospital and urgent care settings.